It has also been reported that a further derivative of the EGFR allosteric inhibitor JBJ0412502 is the EGFR targeting PROTAC, selectively degrades EGFRL858R/T790M and works in conjunction with osimertinib to reduce the proliferation of cancer cells in Ba/F3 cells (Jang et al. 2020). The gene discussed is EGFR; the disease is cancer.